Disclosure Of Cash Flow Statement [Text Block]

GenSight Biologics S.A. - Filing #5982864

Concept As at
2024-12-31
2024-01-01 to
2024-12-31
As at
2023-12-31
As at
2022-12-31
Disclosure of cash flow statement [text block]
Note 11:
Description of accounting policy for determining components of cash and cash equivalents [text block]
4
Cash and cash equivalents if different from statement of financial position [abstract]
Cash and cash equivalents
2 464 EUR
2,134,000 EUR
10,610,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.